Company / EPS (Diluted)
Revolution Medicines, Inc. EPS (Diluted) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$3.86
FY2025
5-year range
-$22.33 / -$2.01
FY2021-FY2025
Trend
-25.3%
vs FY2024
Sector context
#161 of 204
Health Care
What the data says
Revolution Medicines, Inc.'s eps (diluted) of $-3.86 is lower than 79% of companies in the Health Care sector (FY2025). EPS (Diluted) has declined for 3 consecutive years, from $-2.01 in FY2022 to $-3.86 in FY2025.
Based on SEC 10-K filings.
-3.86 in FY2025.
Declined from $-2.57 to $-3.86 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 204This company -$3.86 Sector average -$0.98
▼
-294.0% below sector average
Key checks
Key Insights
- Revolution Medicines, Inc.'s eps (diluted) has declined for 3 consecutive years.
- In FY2025, eps (diluted) decreased 25.3% year-over-year.
- Ranks #161 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.86 | -25.3% |
| FY2024 | -$3.08 | -19.8% |
| FY2023 | -$2.57 | -27.9% |
| FY2022 | -$2.01 | +91.0% |
| FY2021 | -$22.33 | -5.1% |
| FY2020 | -$21.24 | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026